Ładuje się......
AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC
Vassiliki A Papadimitrakopoulou speaks to Roshaine Wijayatunga, Managing Commissioning Editor: Dr Papadimitrakopoulou is the Jay and Lori Eisenberg Distinguished Professor of Medicine and Chief of the section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology a...
Zapisane w:
| Wydane w: | Lung Cancer Manag |
|---|---|
| 1. autor: | |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Future Medicine Ltd
2016
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310333/ https://ncbi.nlm.nih.gov/pubmed/30643560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2017-0001 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|